siRNA
-
【Product for Licensing】A PD-L1 siRNA that Can Boost Immune Response for CHB Functional Cure
If you are interested in this product, please contact us at BD@drugtimes.cn. Many thanks!
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Congratulations to Alnylam and patients who may benefit from this exciting progress!
-
siRNA药物-改变疾病的治疗方式
原文始发于微信公众号（药时代）：siRNA药物-改变疾病的治疗方式 成都先导技术团队编辑丨 【编者按】2020年伊始，新冠病毒席卷全球，“战疫”成为关键词。为早日找到能有效治疗新冠…
